Oricell Therapeutics

原启生物 - 成为创新驱动的全球领先,肿瘤免疫治疗新药的创制者

Shanghai, China · Founded 2019 · $364.0M raised

Headquarters
Shanghai
Employees
51–200
Founded
2019
Business Model
B2B
Total Funding
$364.0M
Last Round
$110.0M Venture RoundApr 2026
Rounds
5

About

Oricell Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative and affordable immunotherapies for hematological malignancies and solid tumors. Its lead program, OriCAR-017, is a GPRC5D-targeting autologous CAR-T therapy for relapsed/refractory multiple myeloma with FDA and NMPA IND approvals. Oricell also advances Ori-C101, a GPC3-targeting CAR-T for hepatocellular carcinoma, leveraging its proprietary OriAb antibody library platform.

Summary

Oricell Therapeutics is an Oncology company based in Shanghai, China, founded in 2019. It has raised $364.0M in total across 5 rounds, most recently a $110.0M Venture Round round in Apr 2026. Investors include Qiming VP, Vivo Capital and Beijing Medical and Health Care Industry Investment Fund.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Venture RoundVenture RoundApr 2026
$110.0M

Sign up to see all 5 rounds

Seed through Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Oricell Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/oricell-therapeutics"><img src="https://indexed.vc/api/badge/company/oricell-therapeutics" alt="Oricell Therapeutics on Indexed.vc" width="260" height="76" /></a>